PTO/SB/05	(11-00

PTO/SB/05 (11-00)
Approved for use through 10/31/2002. OMB 0651-0032
Frademark Office: U.S. DEPARTMENT OF A STATE OF THE S U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

UTILITY **PATENT APPLICATION TRANSMITTAL**

Attorney Docket No.		PC25298A
First Inventor		Joseph Armand Picard
Title	Monocyclic Derivatives a	s Matrix Metalloproteinase Inhibitors
_	14-71-4-11	FF220717590LIS

(Only for new nonprovision	nal applications under 37 CFR 1.53(b)) E	xpress	Mail Label N	D. E	EF22071	7590US
	TION ELEMENTS		ADD	RESS TO:	Box Pater	nt Applicati	
	erning utility patent application conte	ents.	<u></u>		Washingt	on, DC 20	231 🧓
Fee Transmittal Fer (Submit an original and a Applicant claims s See 37 CFR 1.27. 3. Specification (preferred arrangement) - Descriptive title - Cross Reference - Statement Regalate - Reference to se or a computer properties of the Parkey	orm (e.g., PTO/SB/17) duplicate for fee processing) mall entity status. [Total Pages 163] I set forth below) of the invention e to Related Applications arding Fed sponsored R & D quence listing, a table, program listing appendix the Invention of the Invention of the Invention n of the Drawings (if filed) ption Disclosure S.C. 113) [Total Sheets [Total Pages 3 uted (original or copy)]]	(<i>if a</i> a	i i. pape Statements	D-R in duplifigram (Apperino Acid Seessary) eadable Foruence Listin COM or CD-Ir everifying ide Papers (cover (b) Statemer is an assign slation Doce Disclosure DS)/PTO-14	icate, large andix) equence S m (CRF) g on: R (2 copie entity of ab LICATIC er sheet & ent eee) ument (if a	e table or ubmission s); or ove copies DN PARTS document(s)) Power of Attorney
b. Copy from a (for continua) i. DELET Signed sta	prior application (37 CFR 1.63 (d)) tion/divisional with Box 18 completed ION OF INVENTOR(S) tement attached deleting inventor(s)	d)	14. 1	Return Rece (Should be s Certified Co (if foreign pr	pecifically it by of Priority iority is clair	lemized) y Docume ned)	nt(s)
named in the prior application, see 37 CFR 1.63(d)(2) and 1.33(b). 16. Application Data Sheet. See 37 CFR 1.76 Request and Certification under 35 U.S.C. 122 (b)(2)(B)(i). Applicant must attach form PTO/SB/3 or its equivalent. 17. Vother: Certificate of Express Mail					form PTO/SB/35		
18. If a CONTINUING APPLICATION, check appropriate box, and supply the requisite information below and in a preliminary amendment, or in an Application Data Sheet under 37 CFR 1.76: Continuation Divisional Continuation-in-part (CIP) Of prior application No.:/ Prior application information: Examiner Group Art Unit: For CONTINUATION OR DIVISIONAL APPS only: The entire disclosure of the prior application, from which an oath or declaration is supplied under Box 5b, is considered a part of the disclosure of the accompanying continuation or divisional application and is hereby incorporated by reference. The incorporation can only be relied upon when a portion has incorporated from the submitted application parts.							
19. CORPESPONDENCE ADDRESS							
Customer Number or Bar Code Label (Insert Customer NV oc. Allact) pay code label (here) Or Correspondence address below							
Name	Claude F. Purchase, Jr.						
	Warner-Lambert Company						
Address	2800 Plymouth Road						
City	Ann Arbor	S	State	Michigan	Z	ip Code	48105
Country	U.S.A.	Telep	hone	(734) 622-169)2	Fax	(734) 622-1553
Name (Print/Type)	Claude F. Purchase, Jr.		Regi	stration No. (At	tornevlAge	ent) 47,8	371
Signatura	Marida & Quality	440 (5,,,,,90		5/2003

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Box Patent Application, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to re

FEE TRANSMITTAL for FY 2003

Effective 01/01/2003. Patent fees are subject to annual revision.

Applicant claims small entity status. See 37 CFR 1.27

TOTAL AMOUNT OF PAYMENT

(\$) 1	030	.00
--------	-----	-----

spond to a conection of time	ittiation unless it displays a valid OND control furtiber
Co	omplete if Known
Application Number	
Filing Date	
First Named Inventor	Joseph Armand Picard
Examiner Name	
Art Unit	
Attorney Docket No.	PC25298A

METH	OD OF PAYMENT (check all that apply)	FEE CALCULATION (continued)					
Check	Credit card Money Other None	3. ADDITIONAL FEES					
Deposit	Order Order	<u>Large</u>	Entity	Small	Entity		
Deposit		Fee Code	Fee (\$)	Fee Code	Fee	Fee Description	E. Dati
Account	23-0455	1051	130	2051		Surcharge - late filing fee or oath	Fee Paid
Number Deposit	Margar Landont Company	1052	50	2052		Surcharge - late provisional filing fee or	
Account Name	Warner-Lambert Company					cover sheet	\vdash
· ·	ioner is authorized to: <u>(ch</u> eck all that apply)	1053	130	1053		Non-English specification	
Charge fee	(s) indicated below Credit any overpayments		2,520	l		For filing a request for ex parte reexamination	
✓ Charge any	additional fee(s) during the pendency of this application	1804	920*	1804	920*	Requesting publication of SIR prior to Examiner action	
	(s) indicated below, except for the filing fee	1805	1,840*	1805	1,840*	Requesting publication of SIR after Examiner action	
to the above-io	entified deposit account.	1251	110	2251	55	Extension for reply within first month	
	FEE CALCULATION	1252	410	2252	205	Extension for reply within second month	
1. BASIC F Large Entity		1253	930	2253	465	Extension for reply within third month	
Fee Fee	Fee Fee Paid Fee Paid	1254	1,450	2254	725	Extension for reply within fourth month	
Code (\$) 1001 750	Code (\$) 2001 375 Utility filing fee	1255	1,970	2255	985	Extension for reply within fifth month	
1001 750	750.00	1401	320	2401	160	Notice of Appeal	l
1002 530	2002 165 Design filing fee 2003 260 Plant filing fee	1402	320	2402		Filing a brief in support of an appeal	
1003 520	2004 375 Reissue filing fee	1403	280	2403		Request for oral hearing	
1005 160	2005 80 Provisional filing fee	1	1,510	1451		Petition to institute a public use proceeding	
1000 100		1452	110	2452	•	Petition to revive - unavoidable	
	SUBTOTAL (1) (\$) 750.00	1453 1,300 2453 650 Petition to revive - unintentional					
2. EXTRA	CLAIM FEES FOR UTILITY AND REISSUE		1,300	2501		Utility issue fee (or reissue)	
l	Fee from Ext <u>ra Claims below Fee Paid</u>		470	2502		Design issue fee	
Total Claims	14 $-20^{**} = 0$ $\times 0 = 0$	1503	630	2503	315	Plant issue fee	
Independent Claims	3 - 3** = 0 x 0 = 0	1460	130	1460	130	Petitions to the Commissioner	
Multiple Depe	ndent 280 = 280	1807	50	180	7 50	Processing fee under 37 CFR 1.17(q)	
Large Entity		1806	180	1800	6 180	Submission of Information Disclosure Stmt	
Fee Fee Code (\$)	Fee Fee <u>Fee Description</u> Code (\$)	8021	40	802	1 40	Recording each patent assignment per property (times number of properties)	
1202 18 1201 84	2202 9 Claims in excess of 20 2201 42 Independent claims in excess of 3	1809	750	2809	9 375	Filing a submission after final rejection (37 CFR 1.129(a))	
1203 280	2203 140 Multiple dependent claim, if not paid	1810	750	2810	0 375	For each additional invention to be	
1204 84	2204 42 ** Reissue independent claims over original patent	1801	750	2801	375	examined (37 CFR 1.129(b)) Request for Continued Examination (RCE)	
1205 18	2205 9 ** Reissue claims in excess of 20 and over original patent	1802	900	1802	900	Request for expedited examination of a design application	
	SUBTOTAL (2) (\$) 280.00	Other	fee (sp	ecify) _			
**or numbe	r previously paid if greater: For Reissues, see above	*Red	uced by	/ Basic	Filing F	ee Paid SUBTOTAL (3) (\$) 0	

SUBMITTED BY				(Complete (if applicable)
Name (Print/Type)	Claude F. Purchase, Jr.	Registration No. (Attorney/Agent)	47,871	Telephone	734 622-1692
Signature	Claude F. Purchale S.			Date	August 5, 2003

WARNING: Inf rmation on this form may become public. Credit card information should not be included on this f rm. Pr vide credit card inf rmation and authorization on PTO-2038.

This collection of information is required by 37 CFR 1.17 and 1.27. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

CERTIFICATE OF MA Applicant(s): Joseph Armand	Docket No. PC25298A				
Serial No.	Filing Date	Filing Date Examiner			
Invention: MONOCYCLIC DERIVATI	IVES AS MATRIX METALLOPRO	TEINASE INHIBITORS	т от		
			63713 /65/03		
			10		
I hereby certify that this	UTILITY PATENT APPLICATIO				
		(Identify type of correspondence)			
Is being deposited with the	United States Postal Service "Exp	oress Mail Post Office to Addre	essee" service under		
August 5, 2003	e addressed to: MS Patent Applicatio	on, Commissioner for Patents, P.O. B	ox 1450, Alexandria, VA 22313-1450		
On August 3, 2003 (Date)					
			y Dernbach (Person Mailing Confespondence)		
		(Signature of Perso	n Mailing Correspondence)		
			0717590US ' Mailing Label Number)		
	Note: Fash nangr must have	e its own certificate of mailing			
	Note: Each paper must have	Its own certificate of maning			
		•			